New drug M5542 tested in humans for first time

NCT ID NCT06577337

Recruiting now Knowledge-focused Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug called M5542 in 49 healthy adults to see if it is safe and how the body processes it. Participants receive a single injection of either M5542 or a placebo. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M5542

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Clinical Pharmacology Unit of Nuvisan GmbH
RECRUITING

Neu-Ulm, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.